Compare · JNJ vs TSVT
JNJ vs TSVT
Side-by-side comparison of Johnson & Johnson (JNJ) and 2seventy bio Inc. (TSVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and TSVT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $537.39B, about 1460.0x TSVT ($368.1M).
- JNJ has hit the wire 12 times in the past 4 weeks while TSVT has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 17 for TSVT).
- Company
- Johnson & Johnson
- 2seventy bio Inc.
- Price
- $223.61+0.31%
- $4.99+0.00%
- Market cap
- $537.39B
- $368.1M
- 1M return
- -0.24%
- -
- 1Y return
- +45.93%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 17
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
2seventy bio Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
Latest TSVT
- SEC Form 15-12G filed by 2seventy bio Inc.
- Director Glickman Sarah Js returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Casdin Capital, Llc
- Director Leschly Nick returned 335,964 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Eatwell Victoria returned 401,111 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Snow Jessica returned 247,230 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wei Lin returned 17,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Maus Marcela V. returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Newton Charles W. returned 17,092 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Torres Denice returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)